Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?

Annals of Pharmacotherapy

Volumn 42, Issue 7-8, 2008, Pages 1037-1047

  Lam, Stefanie ^a,b   Partovi, Nilufar ^a,c   Ting, Lillian S L ^a   Ensom, Mary H H ^a,d,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c VANCOUVER COASTAL HEALTH   (Canada)

^d Faculty of Pharmaceutical Sciences

^e CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Corticosteroids; Cyclosporine; Glucocorticoids; Immunosuppressants; Mycophenolate; Sirolimus; Tacrolimus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A4; DEXAMETHASONE; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

CORTICOSTEROID THERAPY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TRANSPORT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; TREATMENT WITHDRAWAL;

ADRENAL CORTEX HORMONES; CYCLOSPORINE; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; SIROLIMUS; TACROLIMUS; TRANSPLANTATION;

EID: 48249120712     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K628     Document Type: Review

References (104)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29. DOI 10.1056/NEJMra033540
2. Product monograph. Cellcept (mycophenolate mofetil). Nutley, NJ: Roche Laboratories, March 2003.
3. Kahan BD, Napoli KL. Sirolimus. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied pharmacokinetics & pharmacodynamics. Principles of therapeutic drug monitoring. 4th ed. Baltimore: Lippincott Williams & Wilkins, 2006:595-616.
4. Hiatt WR, Nissen SE, Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration. New drug application 21-628, certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, MD. Circulation 2006;113:e394-5. DOI 10.1161/CIRCULATIONAHA.105.607630
5. Novartis Pharmaceutical Corporation. New Novartis drug Certican approved in first European market. www.novartis.nl/pdf/nieuws/juli2003/ pr230703certicanapprovalsweden.pdf (accessed 2008 Feb 18).
6. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 1998;93:487-90. DOI S0092-8674(00)81177-0
7. Smith L. Corticosteroids in solid organ transplantation: update and review of the literature. J Pharm Pract 2003;16:380-7.
8. Johnston A, Holt DW. Cyclosporine. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied pharmacokinetics & pharmacodynamics. Principles of therapeutic drug monitoring. 4th ed. Baltimore: Lippincott Williams & Wilkins, 2006:512-28.
9. Chapman TM, Perry CM. Everolimus. Drugs 2004:64:861-72; discussion 873-4.
10. Product monograph. Prograf (tacrolimus). Markham, ON: Fujisawa Canada Inc., February 2004.
11. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
12. Shiraga T, Matsuda H, Nagase K, et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 1994;47:727-35. DOI 0006-2952(94)90136-8
13. Augustine JJ, Hricik DE. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 2006;1:1080-9. DOI 10.2215/CJN.01800506
14. Bestard O, Cruzado JM, Grinyo JM. Corticosteroid-sparing strategies in renal transplantation: are we still balancing rejection risk with improved tolerability? Drugs 2006;66:403-14.
15. Fireman M, DiMartini AF, Armstrong SC, Cozza KL. Immunosuppressants. Psychosomatics 2004;45:354-60.
16. Hollander AA, Hene RJ, Hermans J, van Es LA, van der Woude FJ. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997;8:294-301.
17. Lemieux I, Houde I, Pascot A, et al. Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int 2002;62:1839-47. DOI 10.1046/j.1523-1755.2002.00611.x
18. Rigotti P, European Tacrolimus/MMF Transplantation Study Group. Patients with high cholesterol levels benefit most from early withdrawal of corticosteroids. Transplant Proc 2002;34:1797-8. DOI S0041134502030828
19. Ramirez CB, Sebayel MI, Kizilisik T. Early steroid withdrawal after liver transplantation. Transplant Proc 1998;30:3182-3.
20. Rosenbaum DH, Adams BC, Mitchell JD, et al. Effects of early steroid withdrawal after heart transplantation. Ann Thorac Surg 2006;82:637-44; discussion 644. DOI 10.1016/j.athoracsur.2006.03.067
21. Vazquez de Prada JA, Celemin I, de la Torre JM, et al. Corticosteroid withdrawal after heart transplantation. Transplant Proc 1999;31:2212-4.
22. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992;41:1047-55.
23. Christians U, Pokaiyavanichkul T, Chan L. Tacrolimus. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied pharmacokinetics & pharmacodynamics. Principles of therapeutic drug monitoring. 4th ed. Baltimore: Lippincott Williams & Wilkins, 2006:529-62.
24. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
25. Yates CR, Chang C, Kearbey JD, et al. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res 2003;20: 1794-803.
26. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF. Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients. Kidney Int 2004;66:433-40. DOI 10.1111/j.1523-1755.2004.00750.x
27. Konishi H, Sumi M, Shibata N, Takada K, Minouchi T, Yamaji A. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. J Pharm Pharmacol 2004;56:1259-66. DOI 10.1211/0022357044481
28. Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy 2005;25:779-89.
29. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 1989;83:688-97.
30. McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68:356-66. DOI 10.1067/mcp.2000.110215
31. Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004;32:140-8. DOI 10.1124/dmd.32.1.140
32. Kanou M, Usui T, Ueyama H, Sato H, Ohkubo I, Mizutani T. Stimulation of transcriptional expression of human UDP-glucuronosyltransferase 1A1 by dexamethasone. Mol Biol Rep 2004;31:151-8.
33. Djebli N, Picard N, Rerolle JP, Le Meur Y, Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007;17:321-30. DOI 10.1097/FPC.0b013e32801430f8
34. Li YQ, Prentice DA, Howard ML, Mashford ML, Desmond PV. The effect of hormones on the expression of five isoforms of UDP-glucuronosyltransferase in primary cultures of rat hepatocytes. Pharm Res 1999; 16:191-7.
35. Wishart GJ, Dutton GJ. Regulation of onset of development of UDP-glucuronosyltransferase activity towards O-aminophenol by glucocorticoids in late-foetal rat liver in utero. Biochem J 1977;168:507-11.
36. Ueda K, Saeki T, Hirai M, et al. Human P-glycoprotein as a multi-drug transporter analyzed by using transepithelial transport system. Jpn J Physiol 1994;44(suppl 2):S67-71.
37. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-8.
38. Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R. Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett 1999;442:208-14. DOI S0014-5793(98)01663-9
39. Zhao JY, Ikeguchi M, Eckersberg T, Kuo MT. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 1993;133:521-8.
40. Salphati L, Benet LZ. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 1998;55:387-95. DOI S0006-2952(97)00436-X
41. Yokogawa K, Shimada T, Higashi Y, et al. Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. Biochem Pharmacol 2002;63:777-83. DOI S000629520100911X
42. Pulaski L, Kania K, Ratajewski M, Uchiumi T, Kuwano M, Bartosz G. Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol 2005;96:229-34. DOI 10.1016/j.jsbmb.2005.03.004
43. Courtois A, Payen L, Guillouzo A, Fardel O. Up-regulation of multidrug resistance-associated protein 2 (MRP2) expression in rat hepatocytes by dexamethasone. FEBS Lett 1999;459:381-5.
44. Turncliff RZ, Meier PJ, Brouwer KL. Effect of dexamethasone treatment on the expression and function of transport proteins in sandwich-cultured rat hepatocytes. Drug Metab Dispos 2004;32:834-9.
45. Micuda S, Fuksa L, Brcakova E, et al. Zonation of multidrug resistance-associated protein 2 in rat liver after induction with dexamethasone. J Gastroenterol Hepatol 2007. DOI 10.1111/j.1440-1746.2007.05066.x
46. Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 1999;24:321-8.
47. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630-5. DOI 0009-9236(88)90006-9
48. Brunner LJ, Bennett WM, Koop DR. Cyclosporine suppresses rat hepatic cytochrome P450 in a time-dependent manner. Kidney Int 1998;54:216-23. DOI 10.1046/j.1523-1755.1998.00970.x
49. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993;268:6077-80.
50. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002;41:813-51. DOI 411103
51. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005;5:987-94. DOI 10.1046/j.1600-6143.2005.00779.x.
52. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999;21:35-43.
53. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:13-58.
54. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J 2004;6:e28. DOI 10.1208/aapsj060428
55. Miller DS, Flicker G, Drewe J. P-glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J Pharmacol Exp Ther 1997;282:440-4.
56. Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006;70:1019-25. DOI 10.1038/sj.ki.5001649
57. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-21. DOI 10.1056/NEJMra032424
58. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17. DOI 10.1146/annurev. pharmtox.39.1.1
59. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003;3:136-58. DOI 10.1038/sj.tpj.6500171
60. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106:97-132. DOI S0163-7258(04)00200- 1 [pii]; 10.1016/j.pharmthera.2004.10.013
61. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159-68.
62. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997;27:161-70. DOI S0169-409X(97)00041-0
63. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999;62:25-31. DOI S0168-3659(99)00034-6
64. Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 2000;12:3-12. DOI S0928-0987(00)00178-0
65. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001;21:778-96.
66. Lemahieu WP, Maes BD, Vanrenterghem Y. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine. Transplant Proc 2005;37:2051-3. DOI 10.1016/j.transproceed.2005. 03.095
67. Lemahieu WP, Maes BD, Verbeke K, Vanrentenghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 2004;4:1514-22. DOI 10.1111/j.1600-6143.2004.00539.x
68. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43: 623-53.
69. Saitoh H, Saikachi Y, Kobayashi M, et al. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Eur J Pharm Sci 2006;28:34-42. DOI 10.1016/j.ejps.2005.12.006
70. Product monograph. Rapamune (sirolimus). Philadelphia: Wyeth Pharmaceuticals Inc., March 2005.
71. Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992;80:1528-36.
72. Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007;131:1209-18.
73. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 2002;54:1311-31.
74. Klintmalm G, Sawe J. High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients (letter). Lancet 1984;1:731.
75. Huisman RM, van Son WJ, Tegzess AM. Interaction of intravenous methylprednisolone with oral CsA. Nephrol Dial Transplant 1990;5:905-6.
76. Hall TG. Effect of methylprednisolone on cyclosporine blood levels (abstract). Pharmacotherapy 1990;10:248.
77. Ptachcinski RJ, Venkataramanan R, Burckart GJ, et al. Cyclosporine-high-dose steroid interaction in renal transplant recipients: assessment by HPLC. Transplant Proc 1987;19:1728-9.
78. Ubhi CS, Woodhouse L, Giles GR. Interaction of intravenous methylprednisolone with oral cyclosporin. Nephrol Dial Transplant 1990;5: 376-8.
79. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002;62:1060-7. DOI 10.1046/j.1523-1755.2002.00531.x
80. Kuypers DR, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003;43:866-80.
81. Backman L, Kreis H, Morales JM, Wilczek H, Taylor R, Burke JT. Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients. Br J Clin Pharmacol 2002;54:65-8. DOI 10.1046/j.1365-2125.2002.01594.x
82. van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003;16:721-5. DOI 10.1007/s00147-003-0615-1
83. Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003;18:2409-14.
84. Gotti E, Perico N, Perna A, et al. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. J Am Soc Nephrol 2003;14:755-66.
85. Langhoff E, Madsen S, Flachs H, Olgaard K, Ladefoged J, Hvidberg EF. Inhibition of prednisolone metabolism by cyclosporine in kidney-transplanted patients. Transplantation 1985;39:107-9.
86. Ost L. Effects of cyclosporin on prednisolone metabolism (letter). Lancet 1984;1:451.
87. Gregoor PJ, de Sevaux RG, Hene RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999;68:1603-6.
88. Jusko WJ, Ferron GM, Mis SM, Kahan BD, Zimmerman JJ. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. J Clin Pharmacol 1996;36:1100-6.
89. Shimada T, Terada A, Yokogawa K, et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 2002;74: 1419-24. DOI 10.1097/01.TP.0000038287.39271.8F
90. Budde K, Geissler S, Hallebach G, et al. Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up. Transplant Proc 2002;34: 1703-5. DOI S0041134502029901
91. Jeng S, Chanchairujira T, Jusko W, Steiner R. Prednisone metabolism in recipients of kidney or liver transplants and in lung recipients receiving ketoconazole. Transplantation 2003;75:792-5. DOI 10.1097/01.TP.0000055099.97542. 5D
92. Ali Shah I, Whiting PH, Omar G, Thomson AW, Burke MD. Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. Transplant Proc 1991;23:2783-5.
93. Moochhala SM, Lee EJ, Earnest L, Wong JY, Ngoi SS. Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. Transplant Proc 1991;23:2786-8.
94. Piekoszewski W, Chow FS, Jusko WJ. Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. J Pharmacol Exp Ther 1994;269:103-9.
95. van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002;25:707-12.
96. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995;23:1315-24.
97. Yokogawa K, Takahashi M, Tamai I, et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res 1999;16:1213-8.
98. Nawrocki A, Korecka M, Solari S, Kang J, Shaw LM. Mycophenolic acid. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied pharmacokinetics & pharmacodynamics. Principles of therapeutic drug monitoring. 4th ed. Baltimore: Lippincott Williams & Wilkins, 2006: 563-94.
99. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001;40:573-85.
100. Cattaneo D, Merlini S, Pellegrino M, et al. Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 2004;4:1345-51. DOI 10.1111/j.1600-6143.2004. 00517.x
101. Donnenberg VS, Burckart GJ, Griffith BP, Jain AB, Zeevi A, Beng AD. P-Glycoprotein (P-gp) is upregulated in peripheral T-cell subsets from solid organ transplant recipients. J Clin Pharmacol 2001;41:1271-9.
102. Thorn M, Lundgren S, Herlenius G, Ericzon BG, Loof L, Rane A. Gene expression of cytochromes P450 in liver transplants over time. Eur J Clin Pharmacol 2004;60:413-20. DOI 10.1007/s00228-004-0786-4
103. Holt DW, Armstrong VW, Griesmacher A, et al. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring. Ther Drug Monit 2002;24:59-67.
104. Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Ther Drug Monit 2006;28:720-5. DOI 10.1097/FTD.0b013e31802c5cf5